News

Endpoints News39m
No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B
Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...
Endpoints News34m
GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope
GSK to pay $1.2B upfront to Boston Pharmaceuticals for efimosfermin alfa, a MASH drug candidate. Deal includes $800M in ...